Charles Schwab’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-511,623
| Closed | -$9.95M | – | 3213 |
|
|
2018
Q1 | $9.95M | Sell |
511,623
-65,755
| -11% | -$1.29M | 0.01% | 1502 |
|
|
2017
Q4 | $9.61M | Sell |
577,378
-2,171
| -0.4% | -$39.8K | 0.01% | 1499 |
|
|
2017
Q3 | $11.8M | Buy |
579,549
+31,807
| +6% | +$608K | 0.01% | 1301 |
|
|
2017
Q2 | $8.82M | Buy |
547,742
+558
| +0.1% | +$8.24K | 0.01% | 1447 |
|
|
2017
Q1 | $6.92M | Buy |
547,184
+39,801
| +8% | +$481K | 0.01% | 1569 |
|
|
2016
Q4 | $6.72M | Buy |
507,383
+100,564
| +25% | +$1.72M | 0.01% | 1545 |
|
|
2016
Q3 | $9.64M | Sell |
406,819
-4,944
| -1% | -$133K | 0.01% | 1194 |
|
|
2016
Q2 | $11.9M | Buy |
411,763
+76,500
| +23% | +$2.49M | 0.01% | 955 |
|
|
2016
Q1 | $10.7M | Buy |
335,263
+67,743
| +25% | +$2.38M | 0.01% | 1000 |
|
|
2015
Q4 | $11.4M | Buy |
267,520
+8,390
| +3% | +$335K | 0.02% | 925 |
|
|
2015
Q3 | $9.12M | Sell |
259,130
-28,095
| -10% | -$1.27M | 0.01% | 1055 |
|
|
2015
Q2 | $13.2M | Buy |
287,225
+12,934
| +5% | +$614K | 0.02% | 821 |
|
|
2015
Q1 | $12.9M | Buy |
274,291
+46,205
| +20% | +$1.84M | 0.02% | 824 |
|
|
2014
Q4 | $7.23M | Sell |
228,086
-18,987
| -8% | -$556K | 0.01% | 1151 |
|
|
2014
Q3 | $5.86M | Sell |
247,073
-12,459
| -5% | -$319K | 0.01% | 1237 |
|
|
2014
Q2 | $7.78M | Sell |
259,532
-490,589
| -65% | -$13.2M | 0.01% | 1033 |
|
|
2014
Q1 | $19.8M | Buy |
750,121
+5,243
| +0.7% | +$131K | 0.04% | 464 |
|
|
2013
Q4 | $18.7M | Buy |
744,878
+31,508
| +4% | +$703K | 0.04% | 447 |
|
|
2013
Q3 | $15.2M | Buy |
713,370
+59,401
| +9% | +$1.23M | 0.03% | 481 |
|
|
2013
Q2 | $13.3M | Buy |
+653,969
| New | +$11.6M | 0.03% | 488 |
|
Charles Schwab's IPXL Position: Q2 2018 in Review
Charles Schwab sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 511,623 shares — an estimated $9.95M sold.
Charles Schwab first reported a position in IPXL in Q2 2013 and held it in 20 quarters. The position peaked at $19.8M in Q1 2014. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- Charles Schwab reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- Charles Schwab sold 511,623 Impax Laboratories, Inc. shares in Q2 2018, an estimated $9.95M.
- Charles Schwab first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 20 quarters.
- Charles Schwab's Impax Laboratories, Inc. position peaked at $19.8M in Q1 2014.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on Charles Schwab's 13F filing for Q2 2018, filed 8 Aug 2018.